Galectin Therapeutics (GALT) Assets (2010 - 2026)

Galectin Therapeutics' Assets history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• In Q1 2026, Assets rose 65.4% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $15.8 million (up 65.4% YoY), while the FY2025 annual figure was $19.5 million, up 11.64% from the prior year.
• Assets for Q1 2026 stood at $15.8 million, down from $19.5 million in the prior quarter.
• The five-year high for Assets was $33.6 million in Q1 2022, with the low at $9.5 million in Q1 2025.
• The 5-year median for Assets is $20.2 million (2023), against an average of $21.3 million.
• The sharpest annual moves came in 2025 and 2026: Assets sank 63.2% in 2025, then soared 65.4% in 2026.
• Galectin Therapeutics' Assets stood at $21.3 million in 2022, then soared by 32.49% to $28.2 million in 2023, then slumped by 37.96% to $17.5 million in 2024, then increased by 11.64% to $19.5 million in 2025, then dropped by 19.32% to $15.8 million in 2026.
• Business Quant data shows GALT's Assets at $15.8 million in Q1 2026, $19.5 million in Q4 2025, and $12.9 million in Q3 2025.